Brian Park, PharmD

Drug Information Specialist https://www.medicalbag.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

News

Glepaglutide Reduces Need for Parenteral Support in Short Bowel Syndrome Trial

Brian Park, PharmD

September 30, 2022

Positive topline results were announced from a phase 3 trial evaluating glepaglutide in patients with short bowel syndrome.

Medicine

Leniolisib Gets Priority Review for Activated Phosphoinositide 3-Kinase Delta Syndrome

Brian Park, PharmD

September 29, 2022

Leniolisib is a small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K with immunomodulating and potentially antineoplastic activities.

Oncology

Bevacizumab Biosimilar Vegzelma Gets FDA Approval

Brian Park, PharmD

September 28, 2022

Vegzelma is a vascular endothelial growth factor inhibitor.

Ophthalmology

Iheezo Ophthalmic Gel Approved for Ocular Surface Anesthesia

Brian Park, PharmD

September 28, 2022

Iheezo is a sterile, preservative-free, single-patient use, ophthalmic gel preparation.

Neurology

FDA Clears At-Home Monitoring Technology to Aid in Epilepsy Diagnosis

Brian Park, PharmD

September 27, 2022

Seer Home is an ambulatory EEG system designed to be used at the patient’s home for week-long studies.

Medicine

Posimir Now Available for Postsurgical Analgesia Following Shoulder Surgery

Brian Park, PharmD

September 26, 2022

Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered directly into the surgical site.

Medicine

Pfizer, BioNTech Seek to Extend Authorization for Omicron-Adapted Booster to Children

Brian Park, PharmD

September 26, 2022

The bivalent vaccine contains the original strain of the SARS-CoV-2 virus and a strain from the BA.4 and BA.5 lineages of the Omicron variant.

Endocrinology

NIH Study Compares Four Commonly Used Type 2 Diabetes Medications

Brian Park, PharmD

September 22, 2022

The multicenter, randomized, controlled GRADE study was designed to compare the effectiveness of 4 major FDA-approved medications.

Medicine

Diacomit Approved for Younger Patients With Dravet Syndrome

Brian Park, PharmD

September 22, 2022

Diacomit is available as 250mg and 500mg strength capsules in 60-count bottles and as fruit-flavored powder packets for oral suspension in 60-count cartons.

Medicine

Gadopiclenol, a New Macrocyclic Gadolinium-Based Contrast Agent, Gets FDA Approval

Brian Park, PharmD

September 22, 2022

Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs.

Next post in Medicine